Skip to main content

Table 2 Demographic and clinical characteristics of patients

From: Patient experience in systemic lupus erythematosus: development of novel patient-reported symptom and patient-reported impact measures

  CE interviews (n = 41) CD interviews (n = 18)
Gender, n (%)
 Male 2 (5) 1 (6)
 Female 39 (95) 17 (94)
Mean age, years (SD) 47.7 (12.6) 50.8 (14.4)
Ethnicity, n (%)
 Caucasian 22 (55) 7 (39)
 African American 10 (25) 11 (61)
 Latino/Hispanic 5 (12) 0
 Other 2 (5) 0
 Asian 1 (2) 0
Marital status, n (%)
 Married 16 (39) 5 (28)
 Lives with partner 0 1 (6)
 Widowed/divorced/separated 8 (19) 6 (33)
 Single/never married 17 (42) 5 (28)
 No response 0 1 (6)
Employment, n (%)
 Not currently working for pay 11 (27) 2 (11)
 Working full time 11 (27) 4 (22)
 Working part time 1 (2) 2 (11)a
 Retired 6 (15) 5 (28)
 Disabled 0 5 (28)
 Other 12 (29) 0
Mean time since SLE diagnosis, years (SD)b 8.56 (8.13), range < 1–35 (n = 38) 11.28 (10.38), range 1–38 (n = 14)
Mean SELENA-SLEDAIc (SD) 6.02 (3.60) (n = 37) 6.06 (2.53)
Mean SLICC/ACR damage indexc (SD) 5.96 (1.74) (n = 25) 6.00 (1.83) (n = 10)
SLE severity, n (%)
 Mild 22 (54) 9 (50)
 Moderate 18 (44) 9 (50)
 Severe 1 (2) 0
Current SLE treatmentd, n (%)
 Hydroxychloroquine 29 (71) 14 (78)
 Corticosteroids 19 (46) 10 (56)
 NSAIDs 7 (17) 2 (11)
 Belimumab 6 (15) 2 (11)
 Methotrexate 4 (10) 3 (17)
Concomitant conditione, n (%)
 Fibromyalgia 10 (24) 4 (22)
 Osteopenia/osteoporosis 9 (22) 5 (28)
 Anxiety 9 (22) 3 (17)
 Hypertension 8 (20) 4 (22)
 Depression 7 (17) 2 (11)
 Rheumatoid arthritis 5 (12) 1 (6)
 Asthma 4 (10) 2 (11)
 Osteoarthritis 4 (10) 4 (22)
 Sjögren’s syndrome 4 (10) 2 (11)
 Lupus nephritis 3 (7) 4 (22)
 Hyperlipidemia/hypercholesterolemia 2 (5) 3 (17)
 Vasculitis 2 (5) 2 (11)
 Other renal diseases (non-lupus)/ESRD 1 (2) 2 (11)
 Congestive heart failure 0 2 (11)
  1. aOne patient was also a student; bif patients had moved practice since initial SLE diagnosis it was not always possible to precisely determine their date of diagnosis; cwhen data were available; dsome patients were receiving more than 1 treatment; ereported by ≥10% of patients
  2. CE concept elicitation, CD cognitive debriefing, ESRD end stage renal disease, NSAIDs non-steroidal anti-inflammatories, SD standard deviation, SELENA-SLEDAI Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus Disease Activity Index, SLE systemic lupus erythematosus, SLICC/ACR Systemic Lupus International Collaborating Clinics/American College of Rheumatology
\